EORTC CLTF 2021 | Updates on the TELLOMAK trial
Martine Bagot
• 15 Oct 2021
Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, shares early findings from the Phase II TELLOMAK trial (NCT03902184) evaluating the efficacy of lacutamab (IPH4102), an anti-KIR3DL2 monoclonal antibody, alone or in combination with chemotherapy in patients with advanced cutaneous T-cell lymphoma (CTCL). During the EORTC CL group meeting, Dr Bagot presented promising skin results and a tolerable safety profile for cohorts 2 (KIR3DL2 expressing) and 3 (KIR3DL2 non-expressing), both composed of patients with mycosis fungoides (MF). This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
